TY - JOUR
T1 - Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
AU - Tonk, Erwin H J
AU - van Lindert, Anne S R
AU - Verhoeff, Joost J C
AU - Suijkerbuijk, Karijn P M
PY - 2019/5/1
Y1 - 2019/5/1
N2 - In locally advanced non-small cell lung cancer (NSCLC) patients, consolidation therapy with durvalumab (an anti-PD-L1 monoclonal antibody) has proven to significantly increase both progression free and overall survival after chemoradiotherapy. Here, we describe a case of acute pneumonitis during durvalumab administration for locally advanced NSCLC, causing persistent symptomatology and steroid treatment to date. To our knowledge, acute-onset pneumonitis during infusion of a PD-L1 inhibitor has not been described previously. This case illustrates that ICI-induced pneumonitis can occur anytime during treatment, especially after chemoradiation.
AB - In locally advanced non-small cell lung cancer (NSCLC) patients, consolidation therapy with durvalumab (an anti-PD-L1 monoclonal antibody) has proven to significantly increase both progression free and overall survival after chemoradiotherapy. Here, we describe a case of acute pneumonitis during durvalumab administration for locally advanced NSCLC, causing persistent symptomatology and steroid treatment to date. To our knowledge, acute-onset pneumonitis during infusion of a PD-L1 inhibitor has not been described previously. This case illustrates that ICI-induced pneumonitis can occur anytime during treatment, especially after chemoradiation.
KW - Adjuvant
KW - Anti-PD-L1
KW - Immune checkpoint inhibitor
KW - NSCLC
KW - Pneumonitis
UR - http://www.scopus.com/inward/record.url?scp=85070437912&partnerID=8YFLogxK
U2 - 10.1159/000502202
DO - 10.1159/000502202
M3 - Article
C2 - 31543778
SN - 1662-6575
VL - 12
SP - 621
EP - 624
JO - Case Reports in Oncology
JF - Case Reports in Oncology
IS - 2
ER -